{"schema_version":"secwatch.filing_event.v1","accession":"0000937556-23-000063","form_type":"8-K","ticker":"MASI","cik":"0000937556","company_name":"MASIMO CORP","filed_at":"2023-05-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:42.939676+00:00","generated_at":"2026-06-15T11:39:35.562915+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Masimo Q1 2023 revenue $565M (+85.7% YoY), healthcare up 14%; non-GAAP EPS $0.87 beats; FY guidance raised","bullets":["Consolidated revenue $565.0M (+85.7% YoY); healthcare $346.7M (+14.0% reported, +15.8% constant currency).","Non-healthcare (consumer) revenue $218.3M; GAAP EPS $0.39, non-GAAP EPS $0.87.","Full-year 2023 guidance: consolidated revenue $2,415-2,460M; non-GAAP EPS $4.70-4.80.","CEO cites solid performance, new hospital wins, and momentum in consumer health (Opioid Halo, Stork, Freedom pre-order).","Healthcare growth driven by rainbow, Nomoline, Sedline, O3 monitoring uptake."],"urls":{"canonical":"https://secwatch.observer/filing/0000937556-23-000063","json":"https://secwatch.observer/filing/0000937556-23-000063.json","markdown":"https://secwatch.observer/filing/0000937556-23-000063.md","text":"https://secwatch.observer/filing/0000937556-23-000063.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/937556/000093755623000063/0000937556-23-000063-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/937556/000093755623000063/masi-20230509.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-15T11:39:35.562915+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"cdf8477832fbf9575601b918436031ea0e7e4026","claim":"MASIMO CORP reported first quarter of 2023 results: revenue $565.0 million, net income $21.3 million, EPS $0.39 per diluted share. Guidance reaffirmed.","evidence_excerpt":"asimo Reports First Quarter 2023 Financial Results First Quarter 2023 Highlights • Consolidated revenue was $565.0 million; • Healthcare revenue was $346.7 million, representing 14.0% reported growth and 15.8% constant currency growth; • Non-healthcare revenue was $218.3 million; • GAAP earnings per diluted share was $0.39; and • Non-GAAP earnings per diluted share was $0.87.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/937556/000093755623000063/0000937556-23-000063-index.htm","confidence":1.0,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter of 2023"},{"label":"Revenue","value":"$565.0 million"},{"label":"Net income","value":"$21.3 million"},{"label":"EPS","value":"$0.39 per diluted share"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}